GLP-1 Medications: Exploring Their Potential Role in Reducing Dementia Risk
Sandra spends her Tuesday afternoons in a neurologist's waiting room, reflecting on her mother's Alzheimer's diagnosis and the limited treatment options available. As she contemplates her own future, she learns from her mother's neurologist, Dr. Reyes, about the potential of GLP-1 medications—commonly used for weight loss and diabetes—as a possible means of reducing dementia risk. However, Dr. Reyes emphasizes that the evidence is not yet robust enough to recommend these medications specifically for treating Alzheimer's disease.
In late 2025, two major clinical trials investigating the effects of semaglutide on Alzheimer's patients failed to demonstrate significant benefits in slowing cognitive decline. In contrast, a smaller trial involving liraglutide showed promise, revealing a reduction in brain volume loss and cognitive decline. This mixed evidence leads to caution among healthcare professionals regarding the use of GLP-1 medications as a treatment for dementia.
Despite the uncertainty surrounding treatment, a growing body of observational research suggests that GLP-1 medications may lower the risk of developing dementia in the first place. For instance, a 2024 study involving over 1 million patients with type 2 diabetes indicated a 70% lower rate of Alzheimer's diagnoses among semaglutide users compared to those on insulin. Additionally, a 2025 study from the Cleveland Clinic found a significant reduction in Alzheimer's risk associated with the initiation of GLP-1 therapy.
The biological mechanisms behind these findings are plausible. GLP-1 medications are known to improve insulin resistance, reduce inflammation, and enhance vascular health—all factors that contribute to dementia development. However, it is crucial to note that observational studies cannot establish causation and may be influenced by other health-related factors.
One noteworthy detail from the research indicates that the risk of dementia did not significantly differ among all users of GLP-1 medications, but it did decrease by 21% among those who maintained continuous use over several years. This suggests that sustained adherence to the medication may be linked to better outcomes.
For individuals like Sandra, who have a family history of dementia and are considering GLP-1 medications for weight management or diabetes, these findings provide a reason to discuss their options with a healthcare provider. However, for those without other medical reasons to take these medications, the current evidence does not support their use solely for brain health. As ongoing trials continue to explore this connection, it is essential to remain informed and cautious about the implications of these findings.




